Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Cidara Therapeutics (CDTX) EBITDA: 2016-2024

Historic EBITDA for Cidara Therapeutics (CDTX) over the last 9 years, with Dec 2024 value amounting to -$169.8 million.

  • Cidara Therapeutics' EBITDA fell 421.36% to -$83.3 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$184.8 million, marking a year-over-year decrease of 53.10%. This contributed to the annual value of -$169.8 million for FY2024, which is 640.60% down from last year.
  • Per Cidara Therapeutics' latest filing, its EBITDA stood at -$169.8 million for FY2024, which was down 640.60% from -$22.9 million recorded in FY2023.
  • In the past 5 years, Cidara Therapeutics' EBITDA registered a high of -$22.9 million during FY2023, and its lowest value of -$169.8 million during FY2024.
  • In the last 3 years, Cidara Therapeutics' EBITDA had a median value of -$33.6 million in 2022 and averaged -$75.4 million.
  • Per our database at Business Quant, Cidara Therapeutics' EBITDA spiked by 41.11% in 2021 and then crashed by 640.60% in 2024.
  • Cidara Therapeutics' EBITDA (Yearly) stood at -$72.1 million in 2020, then spiked by 41.11% to -$42.5 million in 2021, then increased by 20.92% to -$33.6 million in 2022, then skyrocketed by 31.72% to -$22.9 million in 2023, then tumbled by 640.60% to -$169.8 million in 2024.